Efficacy, safety and tolerability of mometasone furoate 0.1% cream, ointment and lotion in childhood eczema
Keywords:
Childhood eczema, mometasone furoateAbstract
Background Topical corticosteroids have been the first line treatment in children with eczema. Efforts to develop new topical glucocorticoids with reduce systemic bioactivity help to treat them. Mometasone furoate 0.1% has been found to be efficacious in children with atopic dermatitis.Objective To evaluate the therapeutic efficacy, safety and tolerability of mometasone furoate 0.1% cream, ointment and lotion in childhood eczema.Patients and methods The study was conducted from Oct 2007 to Jan 2008 at the outpatient department of dermatology at Abbasi Shaheed Hospital, Karachi. A total of 50 children, aged >12 years, of either sex with all types of childhood eczema were included in the study and those with infection, complication like scars, atrophy, striae, etc, known hypersensitivity to corticosteroids and on any other medicaments were excluded. Parents of children were instructed to apply a thin layer with gentle rubbing twice daily for three weeks. Fingertip unit (FTU) was demonstrated to parents. Tubes of mometasone furoate 0.1% cream, ointment and lotion were given to parents according to the need. Emollient was applied twice daily. Children were followed up at 3, 6 & 12 weeks. SPSS – 13.0 was used for statistical analysis. Friedman test was applied to compare the significance of results at p<0.05.Results Out of 50 patients enrolled, at 3 weeks of follow-up only 43 reported. 29 (67% showed improvement and 14 (32%) fully resolved. At 6 weeks 32 (74.4%) had complete resolution and 7 (16.2%) had improved, but at 12 weeks only 25 patients (58%) had resolved and 6 patients (13.9%) relapsed, while 2 patients were gradually improving. Efficacy in resolution of sign/symptoms on 12 weeks was (p<0.001). No cutaneous or systemic side effects were seen.Conclusion Mometasone furoate 0.1% cream, ointment and lotion are found to be effective, safe and highly tolerable in childhood eczema and the compound was found equally safe in infants.References
Gradman J, Wolthers OD. Short term growth in children with eczema during treatment with topical mometasone furoate and tacrolimus. Acta Paediatr 2007; 96: 1233-7.
Breverk T, Werfel T, Kapp A. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol 2005; 6: 65-77.
Prakash A, Benfield P. Topical mometasone. A review of its pharmacological properties and therapeutic uses in the treatment of dermatological disorders. Drugs 1998; 55: 145-63.
Valotis A, Neukam K, Elert O, Hogger P. Human receptor kinetics, tissue binding affinity and stability of mometasone furoate. J Pharm Sci 2004; 93: 1337-50.
Turpeinen M. Influence of age and severity of dermatitis on the percutaneous absorption of hydrocortisone in children. Br J Dermatol 1988; 118: 517-22.
Fischer G. Compliance problems in pediatric atopic eczema. Aust J Dermatol 1996; 37 (Suppl 1): S10-S13.
Sahasranaman S, Issar M, Hochhaus G. Metabolism of mometasone furoate and biological activity of metabolites. Drug Metab Dispos 2006; 34: 225-33.
Pei AY, Chan HH, Ho KM. The effectiveness of wet wrap dressing using 0.1% mometasone furoate and 0.005% fluticasone propionate ointments in the treatment of moderate to severe atopic dermatitis in children. Pediatr Dermatol 2001; 18: 343-8.
Lebwohl M, Peets E, Chen V. Limited application of mometasone furoate on the face and intertriginous areas: analysis of safety and efficacy. Int J Dermatol 1993; 32: 830-1.
Green C, Colquitt JL, Kirby J et al. Clinical and cost effectiveness of once daily verses more frequent use of same potency topical steroids for topical eczema: a systemic review and economic evaluation. Health Technol Assess 2004; 8: 101-20.
Medansky RS, Bressinck R, Cole GW et al. Mometasone furoate ointment and cream 0.1% in treatment of psoriasis: comparison with ointment and cream formulation of flucinolone acetonide 0.025% and triamcinolone acetonide 0.1%. Cutis 1988; 42: 480-6.
